Jefferies Raises Price Target on Star Bulk Carriers (SBLK) Following 2Q EPS Beat

Go back to Jefferies Raises Price Target on Star Bulk Carriers (SBLK) Following 2Q EPS Beat

Pre-Open Stock Movers 09/15: (AERI) (ACRX) (NTWK) Higher; (SQNS) (PAH) (SRPT) Lower (more...)

September 15, 2016 9:30 AM EDT

Aerie Pharma (NASDAQ: AERI) 65% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.

Sequans Communications S.A.... More

Star Bulk Carriers (SBLK) Prices 11.98M Common Stock Offering at $4.30/Share

September 15, 2016 9:20 AM EDT

Star Bulk Carriers Corp. (Nasdaq: SBLK) announced that it has priced its underwritten public offering of 11,976,745 of its common shares at a price of $4.30 per share. The offering is expected to close on September 20, 2016, subject to customary conditions. The Company intends to use the net proceeds from the offering for general corporate purposes.

Oaktree Capital Management, L.P.... More

Star Bulk Carriers (SBLK) Said to Price Stock Offering at $4.30/Share - Bloomberg

September 15, 2016 9:13 AM EDT

Star Bulk Carriers (NASDAQ: SBLK) said to price its $51.5 million common stock offering at $4.30 per share, according to Bloomberg. SBLK last closed at $4.68.

... More

After-Hours Stock Movers 09/14: (AERI) (ACTG) (ACRX) Higher; (SBLK) (CLC) (SRPT) Lower (more...)

September 14, 2016 6:08 PM EDT

Aerie Pharma (NASDAQ: AERI) 65% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.

Acacia Research (NASDAQ: ACTG) 16% HIGHER; reportedly won a $22 million judgement against Apple

AcelRx... More

Star Bulk Carriers (SBLK) Posts Mixed Q2 Results; Enters Debt Repayment Deferral

September 14, 2016 4:08 PM EDT

Star Bulk Carriers (NASDAQ: SBLK) reported Q2 EPS of ($0.69), $0.03 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $52.65 million versus the consensus estimate of $41.26 million.

As of August 31, 2016 we have entered into Restructuring Letter Agreements (the "RLAs") with all 15... More

Star Bulk Carriers (SBLK) Announces $51.5M Common Stock Offering

September 14, 2016 4:03 PM EDT

Star Bulk Carriers Corp. (Nasdaq: SBLK) announced it plans to make an underwritten public offering for $51.5 million gross proceeds of its common stock. The Company intends to use the net proceeds from the offering for general corporate purposes. Oaktree Capital Management, L.P., Caspian Capital LP... More